Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × belzutifan × Clear all

Status

Sponsor Class

Study Type

Interventional 28 Observational 1

Sponsor

Conditions

von Hippel-Lindau Disease 1

Interventions

Surveys and Questionnaires 477 Blood Specimen Collection 391 Surgical Procedures, Operative 145 Radiotherapy 131 Observation 127 Interviews as Topic 127 Drug Therapy 124 Gene Expression Profiling 118 Biopsy 106 Magnetic Resonance Spectroscopy 105 Immunohistochemistry 100 Data Collection 89 Polymerase Chain Reaction 78 Specimen Handling 73 Amplified Fragment Length Polymorphism Analysis 72 Microarray Analysis 68 Bevacizumab 68 Neoadjuvant Therapy 62 Watchful Waiting 60 Magnetic Resonance Imaging 60 Flow Cytometry 58 Immune Checkpoint Inhibitors 55 Nivolumab 54 Therapeutics 51 pembrolizumab 47 Reverse Transcriptase Polymerase Chain Reaction 47 Immunotherapy 45 Ultrasonography 43 Positron Emission Tomography Computed Tomography 41 Liquid Biopsy 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡